News

A few days in London during the height of the impeachment hearings might be a good respite I somewhat foolishly thought. With the grinding Brexit debate, there is now a furious and contentious sprint to a snap general election on December 12 to largely determine whether the U.K. finally departs the European Union (EU), all of this after a 2016 referendum compelling it to do so.

The first morning after arriving in China last week was the hardest. As I sipped an unusually strong blend of Chinese tea, reading the China Daily, I was pleased to see one of the lead articles describing in glorious detail the health benefits of tea, which evidently was first consumed in 2737 BC in China. Apparently, it has now been shown in a 25-year longitudinal study that tea drinkers had “better organized brain regions” which certainly sounded useful.

After floating a biotech affiliate to the Hong Kong Stock Exchange, Chinese conglomerate Fosun has marched deeper into the health care sector by setting up an international investment alliance consisting of 11 venture capital firms.

Partner companies, such as Parexel, can browse, discover, and license data within HealthVerity’s self-service cloud platform, HealthVerity Marketplace, explained the company’s co-founder and CEO Andrew Kress.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through to Commercialization, and HealthVerity, Inc., the trusted foundation for the rapid creation, exchange and management of healthcare and consumer data, today announced a strategic partnership to expand Parexel’s network of real-world data (RWD) sources to accelerate the delivery of drug development solutions for customers.